Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 15,608 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin and Connective Tissue Disease Clear all
Completed Not applicable Interventional

Cognitive Behavioral Therapy Treatments for Adults With Rheumatoid Arthritis (The SARA Study)

NCT00475111
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Cognitive Behavior Therapy for Pain (CBT-P), Mindfulness Meditation for Emotion Regulation (MM-ER), Rheumatoid arthritis education
Behavioral
Lead sponsor
Arizona State University
Other
Eligibility
21 Years to 75 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 17, 2013 · Synced Oct 30, 2026, 10:39 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

BM Collection From NICU Infants for Composition

NCT02570698
View directory record Official record
Conditions
Diaper Dermatitis
Interventions
Not listed
Lead sponsor
Kimberly-Clark Corporation
Industry
Eligibility
Up to 30 Weeks
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2017 · Synced Oct 30, 2026, 10:39 PM EDT
Completed Phase 1 Interventional

Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients

NCT01363232
View directory record Official record
Conditions
Advanced Solid Tumors, Selected Solid Tumors
Interventions
BKM120 + MEK162
Drug
Lead sponsor
Array Biopharma, now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
5
States / cities
Boston, Massachusetts • Detroit, Michigan • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Oct 30, 2026, 10:39 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo

NCT06602232
View directory record Official record
Conditions
Alopecia Areata, Vitiligo
Interventions
DR-01
Drug
Lead sponsor
Dren Bio
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
12
States / cities
Northridge, California • Miami, Florida • Evans, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 30, 2026, 10:39 PM EDT
Completed Phase 1 Interventional

Cellular Adoptive Immunotherapy in Treating a Patient Who Has Undergone a Donor Stem Cell Transplant for Breast Cancer That Has Spread to the Lung

NCT00301730
View directory record Official record
Conditions
Breast Cancer, Metastatic Cancer
Interventions
aldesleukin, therapeutic tumor infiltrating lymphocytes, trastuzumab, paclitaxel, conventional surgery
Biological · Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Oct 30, 2026, 10:39 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Prospective Radiologic Evaluation of Changes Following Fat Grafting

NCT01343030
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 84 Years · Female only
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Oct 30, 2026, 10:39 PM EDT
Not yet recruiting Not applicable Interventional

Early Intervention

NCT05326165
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Treatment Related Lymphedema
Interventions
Juzo Compression Sleeve and Glove, Compression Sleeve Sensor
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 30, 2026, 10:39 PM EDT
Completed Phase 2 Interventional Results available

6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab

NCT00826267
View directory record Official record
Conditions
Breast Neoplasms
Interventions
lapatinib, BIBW 2992, trastuzumab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 31, 2013 · Synced Oct 30, 2026, 10:39 PM EDT
Terminated Phase 2 Interventional Results available

A Study of TAS-120 in Patients With Metastatic Breast Cancer

NCT04024436
View directory record Official record
Conditions
Metastatic Breast Cancer, FGFR 1 High Amplification, FGFR2 Amplification
Interventions
Futibatinib, Futibatinib plus Fulvestrant
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
17
States / cities
Phoenix, Arizona • San Francisco, California • Fort Myers, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Oct 30, 2026, 10:39 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

NCT05840211
View directory record Official record
Conditions
Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer
Interventions
Sacituzumab Govitecan-hziy, Paclitaxel, Nab-paclitaxel, Capecitabine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
654 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
30
States / cities
Chandler, Arizona • Los Angeles, California • Palo Alto, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Oct 30, 2026, 10:39 PM EDT
Completed Phase 2 Interventional Results available

High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Melanoma

NCT01124734
View directory record Official record
Conditions
Malignant Melanoma
Interventions
Interleukin-2, Temozolomide
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Oct 30, 2026, 10:39 PM EDT
Terminated Not applicable Interventional

Human Amniotic Membrane On Venous Leg Ulcers In an Elderly Population

NCT06544564
View directory record Official record
Conditions
Venous Leg Ulcer
Interventions
Membrane Wrap™, Standard of Care
Device · Other
Lead sponsor
BioLab Holdings
Industry
Eligibility
50 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
9
States / cities
Mesa, Arizona • San Franciso, California • DeLand, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 30, 2026, 10:39 PM EDT
Completed Phase 1 Interventional

Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer

NCT01594398
View directory record Official record
Conditions
Lung Cancer, Non Small Cell Lung Cancer (NSCLC), Breast Cancer, Estrogen Receptor Breast Cancer
Interventions
entinostat, Erlotinib, Exemestane
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Sarasota, Florida • Oklahoma City, Oklahoma • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 19, 2021 · Synced Oct 30, 2026, 10:39 PM EDT
Completed Phase 1 Interventional

Safety Study of a Single Dose of REGN88(SAR153191)in Patients With Rheumatoid Arthritis

NCT01055899
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
REGN88
Biological
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Duncansville, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2013 · Synced Oct 30, 2026, 10:39 PM EDT
Completed Phase 1 Interventional

Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

NCT02046421
View directory record Official record
Conditions
Male Breast Cancer, Recurrent Breast Cancer, Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
mifepristone, carboplatin, gemcitabine hydrochloride, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Chicago, Illinois • Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Oct 30, 2026, 10:39 PM EDT
Recruiting No phase listed Observational

Safe and Explainable AI

NCT06694181
View directory record Official record
Conditions
Artifical Inteligence, Cardiology, Breast Cancer, Sepsis
Interventions
AI-PERSONALIZED CLINICAL DECISION SUPPORT
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
300,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 30, 2026, 10:39 PM EDT
Terminated Phase 2 Interventional Results available

Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer

NCT02874430
View directory record Official record
Conditions
Breast Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Uterine Corpus Cancer, Uterine Corpus Carcinosarcoma
Interventions
Metformin Hydrochloride, Doxycycline
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 30, 2026, 10:39 PM EDT
Completed Phase 2 Interventional Results available

Vitamin D Supplementation as a Neoadjuvant for Photodynamic Therapy of Actinic Keratoses

NCT04140292
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Photodynamic therapy (PDT), Vitamin D3
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 24, 2022 · Synced Oct 30, 2026, 10:39 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Strength Training Intervention for Breast Cancer Survivors and the Effects on Lymphedema Status

NCT00194363
View directory record Official record
Conditions
Lymphedema
Interventions
Strength training
Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
295 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 28, 2017 · Synced Oct 30, 2026, 10:39 PM EDT
Completed Phase 4 Interventional Results available

Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy

NCT04908475
View directory record Official record
Conditions
Psoriasis
Interventions
Risankizumab, Apremilast
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
26
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Oct 30, 2026, 10:39 PM EDT
Completed Phase 4 Interventional

Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab

NCT06806657
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
Garadacimab
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
12 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
6
States / cities
Litchfield Park, Arizona • Bentonville, Arkansas • Orange, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 30, 2026, 10:39 PM EDT
Completed Phase 2 Interventional Results available

Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery

NCT00281957
View directory record Official record
Conditions
Recurrent Melanoma, Stage IV Melanoma
Interventions
sorafenib tosylate, tipifarnib, temsirolimus
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
173
States / cities
Little Rock, Arkansas • Castro Valley, California • Fremont, California + 113 more
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Oct 30, 2026, 10:39 PM EDT
Completed Phase 2 Interventional Results available

Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients

NCT00936221
View directory record Official record
Conditions
Melanoma
Interventions
AZD6244, Dacarbazine, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
Aurora, Colorado • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Oct 30, 2026, 10:39 PM EDT
Completed Phase 2 Interventional Results available

Dexamethasone Solution for the Treatment of Oral Lichen Planus

NCT02850601
View directory record Official record
Conditions
Lichen Planus
Interventions
Dexamethasone
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 30, 2026, 10:39 PM EDT